Energesis Pharmaceuticals
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Bldg 200 Ste 2203, Cambridg...Phone Number
(617) 959-2322Website
www.energesispharma.comRevenue
<$5 MillionIndustry
About Energesis Pharmaceuticals
Energesis Pharmaceuticals is developing therapeutics for diabetes, obesity, and lipid disorders by targeting brown adipose tissue (BAT). The Companys approach is a novel strategy leveraging recent scientific insights in BAT biology to increase the bodys ability to burn stored fat and lower insulin resistance. Diabetes and its major underlying cause, obesity, have reached epidemic proportions in the U.S. and the rest of the industrialized world. However, there are presently very few safe and effective non-invasive treatments for obesity available, and new approaches for diabetes are needed. The company's technology is the first to enable free slots the development of drugs that increase energy expenditure, a strategy for addressing both obesity and diabetes that is strongly supported by the scientific literature. The Energesis management team brings a strong entrepreneurial record together with world-class scientific farmacia maschile, medical, and product development expertise and casiRead more
SIC Code 87,873NAICS Code 54,541Show moreEnergesis Pharmaceuticals Org Chart
Compare Similar Companies to Energesis Pharmaceuticals
Compare insights from companies similar to Energesis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Energesis Pharmaceuticals Tech Stack
A closer look at the technologies used by Energesis Pharmaceuticals
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Energesis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Energesis Pharmaceuticals is developing therapeutics for diabetes, obesity, and lipid disorders by targeting brown adipose tissue (BAT). The Companys approach is a novel strategy leveraging recent scientific insights in BAT biology to increase the bodys ability to burn stored fat and lower insulin resistance. Diabetes and its major underlying cause... Read More